schizophrenia

FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
Xconomy
Sat, 10/10/20 - 11:36 pm
Alkermes
FDA
advisory panels
ALKS 3831
schizophrenia
bipolar disorder
FDA Raises Concern Over Opioid Abuse Related to Alkermes' Schizophrenia Drug
BioSpace
Thu, 10/8/20 - 11:21 pm
Alkermes
FDA
schizophrenia
opioids
ALKS 3831
5 FDA approval decisions to watch in the 4th quarter
BioPharma Dive
Wed, 09/30/20 - 10:45 am
FDA
drug approvals
vaccines
Pfizer
Moderna Therapeutics
COVID-19
Regeneron
EB3
ebola virus
Alkermes
ALKS-3831
schizophrenia
bipolar disorder
Bristol-Myers Squibb
liso-cel
non-Hodgkin lymphoma
roxadustat
FibroGen
chronic kidney disease
Boehringer hopes schizophrenia apps will Click into place
EP Vantage
Tue, 09/15/20 - 10:49 am
digital therapeutics
Boehringer Ingelheim
Click Therapeutics
schizophrenia
CT-155
BioXcel’s phase 3 schizophrenia film has blockbuster potential, say analysts
Pharmaforum
Fri, 09/4/20 - 10:11 am
BioXcel
schizophrenia
bipolar disorder
sublingual treatments
dexmedetomidine
clinical trials
Boehringer calls off €627M deal with GSK spinout, passing on schizophrenia drug option
Endpoints
Wed, 08/26/20 - 11:09 am
Boehringer Ingelheim
GSK
schizophrenia
Autifony
AUT00206
Virtual FDA AdComm for Alkermes' ALKS 3831 adds new focus on drug-drug interactions
Fierce Biotech
Fri, 08/21/20 - 11:36 pm
Alkermes
schizophrenia
bipolar disorder
FDA
ALKS 3831
Lundbeck gets cold feet, axes schizophrenia drug trial
Pharmaforum
Thu, 08/6/20 - 11:03 pm
Lundbeck
schizophrenia
clinical trials
Lu AF11167
Takeda Grants License To Neurocrine Biosciences For Seven Pipeline Programs
NASDAQ
Tue, 06/16/20 - 10:48 am
Takeda
Neurocrine Biosciences
psychiatry
schizophrenia
treatment-resistant depression
anhedonia
Pear rolls out digital therapy for schizophrenia under FDA’s COVID-19 scheme
Pharmaforum
Thu, 04/30/20 - 10:32 am
Pear Therapeutics
digital therapeutics
schizophrenia
FDA
COVID-19
pandemic
Intra-Cellular approval keeps focus on FDA's neuroscience review process
BioPharma Dive
Thu, 12/26/19 - 01:05 pm
FDA
Intra-Cellular Therapies
lumateperone
schizophrenia
Caplyta
3 Biotech Stocks With Big Incoming Catalysts
Motley Fool
Mon, 12/16/19 - 10:52 am
Axsome Therapeutics
AXS-05
Solid Biosciences
SGT-001
Duchenne Muscular Dystrophy
major depressive disorder
Intra-Cellular Therapies
lumateperone
schizophrenia
3 Biotechs Facing FDA Approvals by Year's End
Motley Fool
Mon, 12/9/19 - 09:45 am
FDA
Amgen
Vascepa
Allergan
migraines
ubrogepant
Intra-Cellular Therapies
lumateperone
schizophrenia
4 FDA Dates Biotech Investors Should Circle in December
Motley Fool
Sun, 12/8/19 - 10:24 pm
FDA
Amgen
anti-inflammatories
ABP710
Bausch Health Companies
acne
IDP-123
Intra-Cellular Therapies
lumateperone
schizophrenia
Vascepa
Amarin
AstraZeneca Sells off Seroquel Rights in U.S. and Canada
BioSpace
Tue, 12/3/19 - 10:44 pm
AstraZeneca
Cheplapharm
Seroquel
Seroquel XR
bipolar disorder
schizophrenia
Before 2019 closes, the FDA has 3 key approval decisions to make
Biopharma Dive
Wed, 11/27/19 - 12:43 pm
Allergan
ubrogepant
migraines
Amarin
Vascepa
Intra-Cellular Therapeutics
lumateperone
schizophrenia
bipolar disorder
drug approvals
FDA
Karuna's 'A-ha moment': A billion-dollar stock swing and new expectations
Biopharma Dive
Tue, 11/26/19 - 11:41 pm
Karuna
schizophrenia
KarXT
Karuna Therapeutics Files for $52 Million Offering
CP Wire
Tue, 11/19/19 - 02:36 pm
Karuna Therapeutics
schizophrenia
KarXT
Karuna Therapeutics Files for $52 Million Offering
Tue, 11/19/19 - 02:35 pm
Karuna Therapeutics
schizophrenia
psychosis
KarXT
Karuna Therapeutics Shares Rip Higher After Schizophrenia Drug Aces Midstage Trial
Benzinga
Mon, 11/18/19 - 10:19 am
Karuna Therapeutics
schizophrenia
clinical trials
KarXT

Pages